Title

Rituximab In Immunologic Glomerular Diseases

Keywords

Glomerular diseases; Rejection; Rituximab; Transplant

Abstract

Experimental data suggest that the B-cell antigen CD20 may play a significant role in the pathogenesis of many diseases including glomerular diseases. These and other findings underpin the central concept of B-cell-depleting therapies that target CD20 antigen as treatments for lupus nephritis, idiopathic membranous nephropathy, focal segmental glomerulosclerosis, cryglobulinemic glomerulonephritis, antibody mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft. Use of rituximab as a B-cell depleting therapy has been associated with clinical improvement and has emerged as a possible adjunct or alternative treatment option in this field of nephrology. © 2012 Landes Bioscience.

Publication Date

1-1-2012

Publication Title

mAbs

Volume

4

Issue

2

Number of Pages

198-207

Document Type

Review

Personal Identifier

scopus

DOI Link

https://doi.org/10.4161/mabs.4.2.19286

Socpus ID

84858228135 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/84858228135

This document is currently not available here.

Share

COinS